Canine melanoma study identifies genetic basis of disease, potential drug targets

September 7, 2018 by Steve Yozwiak, Translational Genomics Research Institute
Credit: Translational Genomics Research Institute

As a veterinarian, Dr. Carolyn Duregger is familiar with the telltale signs of canine melanoma. So when she gave her own dog, Parker, a routine oral examination, the 1-centimeter-diameter discolored lump in the pup's upper right gums took her breath away.

"It's an aggressive cancer with poor prognosis that I've seen many times. My stomach dropped. I literally gasped," said Dr. Duregger, recalling the moment she realized her fluffy, 9-year-old Wheaten terrier might be in big trouble.

Dr. Duregger surgically removed the cancerous lump, and started Parker on radiation and an immunotherapy drug. But these measures don't always last, which is why she whole-heartedly supports the molecular-level precision medicine research led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

In the most comprehensive study of its kind, TGen and its collaborators from across the nation used multiple genomic analysis techniques to identify several gene mutations that could be the keys to what drives melanoma in dogs. Following the path from human melanoma, the findings of recurring molecular changes in canine melanoma can help veterinary physicians pinpoint potential new treatments for dogs. Likewise, human physicians will view these changes in light of the type of melanoma that occurs in non-sun exposed areas (as in the case of Parker) in the mouth, or other mucosal surfaces.

Researchers specifically identified mutations in a gene called PTPRJ, a , according to the multi-year study published today in the journal PLOS Genetics.

"This mutational landscape of canine melanoma resembles that seen in human melanoma subtypes found in sun-shaded areas of the body, such as the nose and mouth, which remain difficult to treat. This similarity means that we have a genetic bridge across which understanding of the disease in either species can inform the other," said Dr. Will Hendricks, a TGen Assistant Professor of Integrated Cancer Genomics, and the study's lead author.

While melanoma is commonly associated with skin cancer, different types of melanoma can originate in different parts of the body, and it often spreads to the lungs, lymph nodes, bones and brain.

Researchers looked at 37 canine tumors and 17 control samples from a variety of dog breeds, and used several genomic analysis tools, including: whole genome sequencing, RNA sequencing, array comparative genomic hybridization, single nucleotide polymorphism array, and targeted Sanger sequencing analyses.

"Malignant melanoma is a significant cause of death among domestic dogs, and also provides a powerful comparative model for melanoma among humans," said Dr. Jeffrey Trent, TGen President and Research Director, and the study's senior author. "Overall, these data inform biological comparisons between canine and human melanoma, while suggesting actionable targets for both."

The study found mutations in the PTPRJ tumor suppressor gene in seven of the tumors, and cancer-activating mutations in the RAS gene in nine of the tumors, in addition to changes in the genes MDM2 and TP53.

"Our genetic understanding of canine melanoma now allows us to continue to work to understand melanoma biology, and serves as a roadmap to developing and evaluating new treatment strategies," Dr. Hendricks said.

The study examined several dog breeds with a propensity for melanoma, including Cocker Spaniels, an English Cocker Spaniel and a Labrador retriever. The paper—Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis—notes that an expanded study of breed-specific groups will be critical for further understanding of among .

Explore further: Researchers discover epigenetic reason for drug resistance in a deadly melanoma

More information: William P. D. Hendricks et al. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis, PLOS Genetics (2018). DOI: 10.1371/journal.pgen.1007589

Related Stories

Researchers discover epigenetic reason for drug resistance in a deadly melanoma

August 24, 2018
Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse ...

Researchers map DNA damage links to onset of skin cancer, melanoma

July 6, 2018
A critical link in mapping recurrent mutations of melanoma—the most serious form of skin cancer in humans—has been discovered by researchers at Washington State University School of Molecular Biosciences, in collaboration ...

Loss of cilia leads to melanoma

July 2, 2018
Most cells in the human body have a cilium, a slender cell protuberance that picks up signals from the cell's external environment. Researchers at the University of Zurich have now shown that these fine sensory antennae play ...

Role of melanoma-promoting protein revealed

December 6, 2017
In a new study, Yale researchers describe the role of a protein that promotes growth of melanoma, the deadliest form of skin cancer.

Scientists identify novel therapeutic targets for metastatic melanoma

November 27, 2017
Mount Sinai researchers have identified novel therapeutic targets for metastatic melanoma, according to a study published in Molecular Cell.

Dogs accelerate the advance of new cancer treatments for both pets and people

February 4, 2016
A Science Translational Medicine review suggests integrating dogs with naturally occurring cancers into studies of new drug therapeutics could result in better treatments for our four-legged friends while helping inform therapeutic ...

Recommended for you

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

Proposed cancer treatment may boost lung cancer stem cells, study warns

November 20, 2018
Epigenetic therapies—targeting enzymes that alter what genes are turned on or off in a cell—are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant. Researchers at Boston ...

Aspirin and omega-3 reduce pre-cancerous bowel polyps

November 19, 2018
Both aspirin and a purified omega-3, called EPA, reduce the number of pre-cancerous polyps in patients found to be at high risk of developing bowel cancer, according to new research.

New drug discovery could halt spread of brain cancer

November 19, 2018
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.